# US 2023/0066737 A1 · Preparation of semicarbazide-sensitive amine oxidase inhibitor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066737 A1
- Document ID: US20230066737A1
- Status: Published application
- Kind: A1
- Application number: 17/759,341
- Filed: 2021-01-25
- Published: 2023-03-02
- Earliest claimed: 2020-01-23
- Assignees: Ennovabio (Zhejiang) Pharmaceuticals Co., Ltd.; Shanghai Ennovabio Pharmaceuticals Co., Ltd.
- Applicants: Ennovabio (Zhejiang) Pharmaceuticals Co., Ltd.; Shanghai Ennovabio Pharmaceuticals Co., Ltd.
- Inventors: Shengyang LIU; Jianwen DENG; Zhiyong FENG; Lei JIANG; Zhi QIAO; Ke SHANG; Xiaoping XIE; Xueli XU; Yuan XU; Haixia ZHAO
- Web page: https://patentgrep.com/patent/US20230066737A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides preparation of a semicarbazide-sensitive amine oxidase inhibitor and use thereof. In particular, disclosed in the present invention are a compound as represented by formula I, or a stereoisomer or a racemate or a pharmaceutically acceptable salt of the compound. Also disclosed in the present invention is that the compound can inhibit semicarbazide-sensitive amine oxidase.

## Claims

### Claim 1

A compound of formula I, or a stereoisomer, a racemate or a pharmaceutically acceptable salt thereof:
wherein,
A is selected from the groups consisting of a substituted or unsubstituted 5-12 membered heteroaromatic ring;
R1 is selected from the groups consisting of H, a substituted or unsubstituted C 1-C8 alkyl, substituted or unsubstituted-(CH2)m-O-C1-C8 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, -C(O)NR4R5;
m is selected from the groups consisting of: 1, 2, 3 and 4;
R2, R3 are each independently selected from the groups consisting of H, F, —OH, ═O, -CN, a substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted-O-C1-C8 alkyl, substituted or unsubstituted-O-C3-C8 cycloalkyl, substituted or unsubstituted-C6-C10 aryl, substituted or unsubstituted-O-C1-C4 alkyl-C6-C10 aryl, substituted or unsubstituted-S-C1-C8 alkyl; or R2, R3 individually or together with the carbon atom to which they are attached form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring (R2, R3 are attached to the same or different carbon atom);
R4, R5 are each independently selected from the groups consisting of H, —OH, a substituted or unsubstituted C1-C8-alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted -C6-C10 aryl, substituted or unsubstituted -C1-C4 alkyl (C6-C10 aryl), substituted or unsubstituted -C1-C4 alkyl (C3-C8 cycloalkyl); or R4, R5 together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-8 membered heterocyclic group;
provided that the above-mentioned groups together form a chemically stable structure; unless otherwise specified, the above-mentioned cycloalkyl, heterocyclyl, aryl and heteroaryl groups include any ring form, including monocyclic, condensed, bridged or spirocyclic ring;
unless otherwise specified, the “substituted” means that one or more hydrogen atoms on a group are substituted with a substituent selected from the groups consisting of oxo(=O), hydroxy, substituted or unsubstituted C5-C6 cycloalkyl, substituted or unsubstituted 5-6 membered heterocycle containing 1 nitrogen atom, 4-6 membered heterocycle containing 1 oxygen atom, C1-C6 alkyl, C1-C6 alkoxy, fluoro C1-C6 alkoxy, C1-C6 alkoxy substituted C1-C6alkoxy, C1-C6 alkylcarbonyl, C2-C6 amide, C1-C6 alkyl-NH-, (C1-C6 alkyl)(C1-C6 alkyl)N-; and the “substituted: means that the above groups are substituted with a group selected from a C1-C6 alkoxy, or C1-C6 alkylcarbonyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a stereoisomer, racemate, or the pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the groups consisting of H, F, ═O, —CN, substituted or unsubstituted C1-C8-alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted-O-C1-C8 alkyl, substituted or unsubstituted-O-C3-C8 cycloalkyl; or R2 and R3 independently or together with the carbon atoms to which they are attached form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring (R2 and R3 are attached to the same or different carbon atom).

### Claim 3 (depends on 1)

The compound of claim 1, or a stereoisomer or racemate thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is a substituted or unsubstituted 5-7 membered heteroaromatic ring.

### Claim 4 (depends on 1)

The compound of claim 1, or a stereoisomer or racemate thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is selected from the groups consisting of
.

### Claim 5 (depends on 1)

The compound of claim 1, or a stereoisomer or racemate thereof, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I has a structure shown in the following formula:
.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any of claims 1-5, wherein the compound is selected from the groups consisting of:
.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition, comprising therapeutically effective amount of the compound according to any one of claim 1-6, or stereoisomers or racemates thereof, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is used for preventing and/or treating diseases related to SSAO or regulated by SSAO/VAP-1 protein; preferably, the diseases are selected from the group consisting of inflammatory diseases and/or inflammation-related diseases, diabetes and/or diabetes-related diseases, mental disorders, ischemic diseases, vascular diseases, ocular diseases, fibrosis, neuroinflammatory diseases, pain-related diseases, cancer or tissue transplant rejection.

### Claim 9 (depends on 1, 7)

Use of the compound of claim 1, or a stereoisomer or racemate thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 7, in the preparation of drugs for preventing and/or treating diseases related to SSAO or regulated by SSAO/VAP-1 protein.

### Claim 10 (depends on 9)

The use of claim 9, wherein the diseases related to SSAO or regulated by the SSAO/VAP-1 protein are selected from the group consisting of inflammatory diseases and/or inflammation-related diseases, diabetes and/or diabetes related diseases, mental disorders, pain related diseases, ischemic diseases, vascular diseases, ocular diseases, fibrosis, neuroinflammatory diseases, cancer, fibrosis and tissue transplant rejection.
